Crinetics Pharmaceuticals, Inc. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Crinetics Pharmaceuticals, Inc. stock issued during period, value, new issues for the quarter ending 2026-06-30 was $0.00.
- Crinetics Pharmaceuticals, Inc. stock issued during period, value, new issues for the quarter ending 2026-03-31 was $379.77M.
- Crinetics Pharmaceuticals, Inc. stock issued during period, value, new issues for the quarter ending 2024-12-31 was $542.85M, a 1754.75% increase year-over-year.
- Crinetics Pharmaceuticals, Inc. stock issued during period, value, new issues for the quarter ending 2024-09-30 was $48.30M, a 85.30% decline year-over-year.
- Crinetics Pharmaceuticals, Inc. stock issued during period, value, new issues for fiscal 2024 was $970.05M, a 162.83% increase from fiscal 2023.
- Crinetics Pharmaceuticals, Inc. stock issued during period, value, new issues for fiscal 2023 was $369.08M, a 214.80% increase from fiscal 2022.
- Crinetics Pharmaceuticals, Inc. stock issued during period, value, new issues for fiscal 2022 was $117.24M, a 53.02% decline from fiscal 2021.
- Crinetics Pharmaceuticals, Inc. stock issued during period, value, new issues for fiscal 2021 was $249.54M, a 118.35% increase from fiscal 2020.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | |
| 2026-03-31 | $379.77M 10-Q · filed 2026-05-07 | |
| 2024-12-31 | $542.85M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $970.05M 10-K · filed 2026-02-26 |
| 2024-09-30 | $48.30M 10-Q · filed 2025-11-06 | $456.47M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $14.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $736.67M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $378.89M 10-Q · filed 2025-05-08 | $747.97M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $29.27M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $369.08M 10-K · filed 2026-02-26 |
| 2023-09-30 | $328.50M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $11.31M 10-Q · filed 2024-08-08 | |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $117.24M 10-K · filed 2025-02-27 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | |
| 2022-06-30 | $117.24M 10-Q · filed 2023-08-08 | |
| 2021-12-31 | $162.01M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $249.54M 10-K · filed 2024-02-28 |
| 2021-09-30 | $14.98M 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $72.56M 10-Q · filed 2022-08-12 | |
| 2020-12-31 | $6.43M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $114.28M 10-K · filed 2023-02-28 |
| 2020-09-30 | -$6.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-05 | |
| 2020-06-30 | $107.86M 10-Q · filed 2021-08-10 | |
| 2020-03-31 | $6.43M 10-Q · filed 2021-05-06 | |
| 2018-12-31 | $106.47M 10-K · filed 2021-03-30 |